Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:36 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
NCT03606174 · Mirati Therapeutics Inc. · PHASE2 · terminated · last registry update 2023-08-24 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated due to sponsor decision / portfolio prioritization, and not due to safety reasons.” | – | Registry record, Mirati Therapeutics Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDCD1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-08-23Phase 3 first posted: National Cancer Institute (NCI), Cemiplimab (NCT06568172)
- 2024-08-20Phase 3 first posted: Bristol-Myers Squibb, Nivolumab + Relatlimab (NCT06561386)
- 2024-08-16Phase 3 first posted: NovoCure GmbH, Temozolomide + Pembrolizumab (NCT06556563)
- 2024-08-09Phase 3 first posted: Ferring Pharmaceuticals, Nadofaragene Firadenovec + Gemcitabine (NCT06545955)
- 2024-07-29Phase 3 first posted: National Cancer Institute (NCI), Carboplatin + Cisplatin (NCT06524544)
- 2024-07-29Phase 3 first posted: Genmab, Petosemtamab + Pembrolizumab (NCT06525220)
- 2024-06-20Results posted on the registry: Eli Lilly and Company, Selpercatinib + Carboplatin (NCT04194944)
- 2024-06-11Phase 3 first posted: Bayer, Sevabertinib + Pembrolizumab (NCT06452277)
- 2024-05-21Phase 3 first posted: National Cancer Institute (NCI), Doxorubicin + Pembrolizumab (NCT06422806)
- 2024-05-20Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + sac-TMT (NCT06422143)
- 2024-05-01Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + Sacituzumab tirumotecan (NCT06393374)
- 2024-04-23Results posted on the registry: National Cancer Institute (NCI), Pembrolizumab (NCT02775851)
- 2024-04-10Phase 3 first posted: AstraZeneca, Datopotamab Deruxtecan + Rilvegostomig (NCT06357533)
- 2024-04-04Phase 3 first posted: Samsung Bioepis Co., Ltd., SB27 + Keytruda (NCT06348199)
- 2024-04-03Phase 3 first posted: Merck Sharp & Dohme LLC, Calderasib + Pembrolizumab (NCT06345729)
- 2024-03-15Phase 3 first posted: Merck Sharp & Dohme LLC, Sacituzumab tirumotecan + Pembrolizumab (NCT06312137)
- 2024-03-06Phase 3 first posted: Inhibrx Biosciences, Inc, INBRX-106 + Pembrolizumab (NCT06295731)
- 2024-02-28Phase 3 first posted: Jazz Pharmaceuticals, Zanidatamab + Cisplatin (NCT06282575)
- 2024-02-07Phase 3 first posted: Regeneron Pharmaceuticals, fianlimab + cemiplimab (NCT06246916)
- 2024-02-01Results posted on the registry: City of Hope Medical Center, Pembrolizumab + Vorinostat (NCT03150329)
- 2024-02-01Phase 3 first posted: AbbVie, Livmoniplimab + Budigalimab (NCT06236438)
- 2024-01-22Phase 3 first posted: NovoCure GmbH, Pembrolizumab + Platinum based chemotherapy (NCT06216301)
- 2023-12-14Phase 3 first posted: Merck Sharp & Dohme LLC, Sacituzumab tirumotecan + Pembrolizumab (NCT06170788)
- 2023-11-21Results posted on the registry: National Cancer Institute (NCI), Pembrolizumab (NCT03698019)
- 2023-11-07Phase 3 first posted: Eli Lilly and Company, LY3537982 + Pembrolizumab (NCT06119581)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision